nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—Protein Kinase Inhibitors—Sunitinib—pancreatic cancer	0.645	1	CiPCiCtD
Sirolimus—SLCO1B1—Irinotecan—pancreatic cancer	0.0192	0.0965	CbGbCtD
Sirolimus—CYP3A7—Tamoxifen—pancreatic cancer	0.0147	0.0737	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Tamoxifen—pancreatic cancer	0.0147	0.0737	CbGbCtD
Sirolimus—CYP3A7—Irinotecan—pancreatic cancer	0.0113	0.0566	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Irinotecan—pancreatic cancer	0.0113	0.0566	CbGbCtD
Sirolimus—CYP3A5—Tamoxifen—pancreatic cancer	0.011	0.0553	CbGbCtD
Sirolimus—CYP3A5—Erlotinib—pancreatic cancer	0.00938	0.047	CbGbCtD
Sirolimus—CYP3A5—Irinotecan—pancreatic cancer	0.00847	0.0425	CbGbCtD
Sirolimus—CYP3A7—Docetaxel—pancreatic cancer	0.00828	0.0415	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Docetaxel—pancreatic cancer	0.00828	0.0415	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Sunitinib—pancreatic cancer	0.00824	0.0413	CbGbCtD
Sirolimus—CYP3A7—Sunitinib—pancreatic cancer	0.00824	0.0413	CbGbCtD
Sirolimus—ABCB1—Tamoxifen—pancreatic cancer	0.00718	0.036	CbGbCtD
Sirolimus—CYP3A5—Docetaxel—pancreatic cancer	0.00621	0.0311	CbGbCtD
Sirolimus—ABCB1—Gemcitabine—pancreatic cancer	0.00619	0.031	CbGbCtD
Sirolimus—CYP3A5—Sunitinib—pancreatic cancer	0.00618	0.031	CbGbCtD
Sirolimus—ABCB1—Erlotinib—pancreatic cancer	0.0061	0.0306	CbGbCtD
Sirolimus—ABCB1—Irinotecan—pancreatic cancer	0.00551	0.0276	CbGbCtD
Sirolimus—CYP3A4—Tamoxifen—pancreatic cancer	0.0043	0.0216	CbGbCtD
Sirolimus—ABCB1—Docetaxel—pancreatic cancer	0.00404	0.0203	CbGbCtD
Sirolimus—ABCB1—Sunitinib—pancreatic cancer	0.00402	0.0202	CbGbCtD
Sirolimus—CYP3A4—Erlotinib—pancreatic cancer	0.00366	0.0183	CbGbCtD
Sirolimus—CYP3A4—Irinotecan—pancreatic cancer	0.0033	0.0166	CbGbCtD
Sirolimus—ABCB1—Doxorubicin—pancreatic cancer	0.00301	0.0151	CbGbCtD
Sirolimus—CYP3A4—Docetaxel—pancreatic cancer	0.00242	0.0121	CbGbCtD
Sirolimus—CYP3A4—Sunitinib—pancreatic cancer	0.00241	0.0121	CbGbCtD
Sirolimus—CYP3A4—Doxorubicin—pancreatic cancer	0.0018	0.00905	CbGbCtD
Sirolimus—EIF4E—pancreas—pancreatic cancer	0.000584	0.184	CbGeAlD
Sirolimus—FGF2—islet of Langerhans—pancreatic cancer	0.000507	0.159	CbGeAlD
Sirolimus—EIF4E—digestive system—pancreatic cancer	0.000499	0.157	CbGeAlD
Sirolimus—MTOR—pancreas—pancreatic cancer	0.000226	0.071	CbGeAlD
Sirolimus—FKBP1A—pancreas—pancreatic cancer	0.000203	0.0639	CbGeAlD
Sirolimus—MTOR—digestive system—pancreatic cancer	0.000193	0.0606	CbGeAlD
Sirolimus—FKBP1A—digestive system—pancreatic cancer	0.000174	0.0545	CbGeAlD
Sirolimus—SLC47A1—digestive system—pancreatic cancer	0.000149	0.0469	CbGeAlD
Sirolimus—SLCO1B1—digestive system—pancreatic cancer	0.000147	0.0463	CbGeAlD
Sirolimus—CYP3A5—islet of Langerhans—pancreatic cancer	0.000126	0.0396	CbGeAlD
Sirolimus—CYP3A5—pancreas—pancreatic cancer	8.85e-05	0.0278	CbGeAlD
Sirolimus—CYP3A5—digestive system—pancreatic cancer	7.56e-05	0.0238	CbGeAlD
Sirolimus—ABCB1—islet of Langerhans—pancreatic cancer	6.69e-05	0.021	CbGeAlD
Sirolimus—CYP3A4—digestive system—pancreatic cancer	5.67e-05	0.0178	CbGeAlD
Sirolimus—ABCB1—pancreas—pancreatic cancer	4.7e-05	0.0148	CbGeAlD
Sirolimus—ABCB1—digestive system—pancreatic cancer	4.01e-05	0.0126	CbGeAlD
Sirolimus—Hyperglycaemia—Epirubicin—pancreatic cancer	3.26e-05	0.000362	CcSEcCtD
Sirolimus—Cough—Docetaxel—pancreatic cancer	3.26e-05	0.000362	CcSEcCtD
Sirolimus—Hypersensitivity—Irinotecan—pancreatic cancer	3.25e-05	0.000361	CcSEcCtD
Sirolimus—Pneumonia—Epirubicin—pancreatic cancer	3.24e-05	0.00036	CcSEcCtD
Sirolimus—Hypertension—Docetaxel—pancreatic cancer	3.23e-05	0.000358	CcSEcCtD
Sirolimus—Infestation NOS—Epirubicin—pancreatic cancer	3.22e-05	0.000358	CcSEcCtD
Sirolimus—Infestation—Epirubicin—pancreatic cancer	3.22e-05	0.000358	CcSEcCtD
Sirolimus—Bronchitis—Doxorubicin—pancreatic cancer	3.22e-05	0.000357	CcSEcCtD
Sirolimus—Arthralgia—Docetaxel—pancreatic cancer	3.18e-05	0.000353	CcSEcCtD
Sirolimus—Myalgia—Docetaxel—pancreatic cancer	3.18e-05	0.000353	CcSEcCtD
Sirolimus—Chest pain—Docetaxel—pancreatic cancer	3.18e-05	0.000353	CcSEcCtD
Sirolimus—Nausea—Sunitinib—pancreatic cancer	3.18e-05	0.000353	CcSEcCtD
Sirolimus—Pancytopenia—Doxorubicin—pancreatic cancer	3.18e-05	0.000353	CcSEcCtD
Sirolimus—Asthenia—Irinotecan—pancreatic cancer	3.16e-05	0.000351	CcSEcCtD
Sirolimus—Neuropathy peripheral—Epirubicin—pancreatic cancer	3.16e-05	0.000351	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	3.16e-05	0.000351	CcSEcCtD
Sirolimus—Stomatitis—Epirubicin—pancreatic cancer	3.14e-05	0.000349	CcSEcCtD
Sirolimus—Urinary tract infection—Epirubicin—pancreatic cancer	3.13e-05	0.000348	CcSEcCtD
Sirolimus—Conjunctivitis—Epirubicin—pancreatic cancer	3.13e-05	0.000348	CcSEcCtD
Sirolimus—Dysuria—Doxorubicin—pancreatic cancer	3.13e-05	0.000347	CcSEcCtD
Sirolimus—Neutropenia—Doxorubicin—pancreatic cancer	3.13e-05	0.000347	CcSEcCtD
Sirolimus—Hypersensitivity—Fluorouracil—pancreatic cancer	3.11e-05	0.000345	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	3.11e-05	0.000345	CcSEcCtD
Sirolimus—Sweating—Epirubicin—pancreatic cancer	3.09e-05	0.000343	CcSEcCtD
Sirolimus—Pollakiuria—Doxorubicin—pancreatic cancer	3.09e-05	0.000343	CcSEcCtD
Sirolimus—Asthenia—Gemcitabine—pancreatic cancer	3.08e-05	0.000342	CcSEcCtD
Sirolimus—Haematuria—Epirubicin—pancreatic cancer	3.07e-05	0.000341	CcSEcCtD
Sirolimus—Confusional state—Docetaxel—pancreatic cancer	3.07e-05	0.000341	CcSEcCtD
Sirolimus—Hepatobiliary disease—Epirubicin—pancreatic cancer	3.05e-05	0.000338	CcSEcCtD
Sirolimus—Anaphylactic shock—Docetaxel—pancreatic cancer	3.05e-05	0.000338	CcSEcCtD
Sirolimus—Oedema—Docetaxel—pancreatic cancer	3.05e-05	0.000338	CcSEcCtD
Sirolimus—Weight increased—Doxorubicin—pancreatic cancer	3.05e-05	0.000338	CcSEcCtD
Sirolimus—Epistaxis—Epirubicin—pancreatic cancer	3.04e-05	0.000338	CcSEcCtD
Sirolimus—Pruritus—Gemcitabine—pancreatic cancer	3.04e-05	0.000337	CcSEcCtD
Sirolimus—Infection—Docetaxel—pancreatic cancer	3.03e-05	0.000336	CcSEcCtD
Sirolimus—Weight decreased—Doxorubicin—pancreatic cancer	3.03e-05	0.000336	CcSEcCtD
Sirolimus—Sinusitis—Epirubicin—pancreatic cancer	3.03e-05	0.000336	CcSEcCtD
Sirolimus—Hyperglycaemia—Doxorubicin—pancreatic cancer	3.02e-05	0.000335	CcSEcCtD
Sirolimus—Diarrhoea—Irinotecan—pancreatic cancer	3.02e-05	0.000335	CcSEcCtD
Sirolimus—Pneumonia—Doxorubicin—pancreatic cancer	3e-05	0.000333	CcSEcCtD
Sirolimus—Shock—Docetaxel—pancreatic cancer	3e-05	0.000333	CcSEcCtD
Sirolimus—Nervous system disorder—Docetaxel—pancreatic cancer	2.99e-05	0.000332	CcSEcCtD
Sirolimus—Pruritus—Fluorouracil—pancreatic cancer	2.99e-05	0.000332	CcSEcCtD
Sirolimus—Thrombocytopenia—Docetaxel—pancreatic cancer	2.99e-05	0.000331	CcSEcCtD
Sirolimus—Infestation NOS—Doxorubicin—pancreatic cancer	2.98e-05	0.000331	CcSEcCtD
Sirolimus—Infestation—Doxorubicin—pancreatic cancer	2.98e-05	0.000331	CcSEcCtD
Sirolimus—Tachycardia—Docetaxel—pancreatic cancer	2.98e-05	0.00033	CcSEcCtD
Sirolimus—Skin disorder—Docetaxel—pancreatic cancer	2.96e-05	0.000329	CcSEcCtD
Sirolimus—Diarrhoea—Gemcitabine—pancreatic cancer	2.94e-05	0.000326	CcSEcCtD
Sirolimus—Neuropathy peripheral—Doxorubicin—pancreatic cancer	2.92e-05	0.000325	CcSEcCtD
Sirolimus—Dizziness—Irinotecan—pancreatic cancer	2.92e-05	0.000324	CcSEcCtD
Sirolimus—Haemoglobin—Epirubicin—pancreatic cancer	2.91e-05	0.000323	CcSEcCtD
Sirolimus—Stomatitis—Doxorubicin—pancreatic cancer	2.91e-05	0.000323	CcSEcCtD
Sirolimus—Anorexia—Docetaxel—pancreatic cancer	2.91e-05	0.000323	CcSEcCtD
Sirolimus—Rhinitis—Epirubicin—pancreatic cancer	2.9e-05	0.000322	CcSEcCtD
Sirolimus—Urinary tract infection—Doxorubicin—pancreatic cancer	2.9e-05	0.000322	CcSEcCtD
Sirolimus—Conjunctivitis—Doxorubicin—pancreatic cancer	2.9e-05	0.000322	CcSEcCtD
Sirolimus—Haemorrhage—Epirubicin—pancreatic cancer	2.89e-05	0.000321	CcSEcCtD
Sirolimus—Diarrhoea—Fluorouracil—pancreatic cancer	2.89e-05	0.000321	CcSEcCtD
Sirolimus—Hypoaesthesia—Epirubicin—pancreatic cancer	2.88e-05	0.00032	CcSEcCtD
Sirolimus—Pharyngitis—Epirubicin—pancreatic cancer	2.87e-05	0.000319	CcSEcCtD
Sirolimus—Sweating—Doxorubicin—pancreatic cancer	2.86e-05	0.000317	CcSEcCtD
Sirolimus—Urinary tract disorder—Epirubicin—pancreatic cancer	2.86e-05	0.000317	CcSEcCtD
Sirolimus—Oedema peripheral—Epirubicin—pancreatic cancer	2.85e-05	0.000316	CcSEcCtD
Sirolimus—Hypotension—Docetaxel—pancreatic cancer	2.85e-05	0.000316	CcSEcCtD
Sirolimus—Haematuria—Doxorubicin—pancreatic cancer	2.84e-05	0.000316	CcSEcCtD
Sirolimus—Connective tissue disorder—Epirubicin—pancreatic cancer	2.84e-05	0.000316	CcSEcCtD
Sirolimus—Urethral disorder—Epirubicin—pancreatic cancer	2.84e-05	0.000315	CcSEcCtD
Sirolimus—Hepatobiliary disease—Doxorubicin—pancreatic cancer	2.82e-05	0.000313	CcSEcCtD
Sirolimus—Epistaxis—Doxorubicin—pancreatic cancer	2.81e-05	0.000312	CcSEcCtD
Sirolimus—Vomiting—Irinotecan—pancreatic cancer	2.8e-05	0.000311	CcSEcCtD
Sirolimus—Sinusitis—Doxorubicin—pancreatic cancer	2.8e-05	0.000311	CcSEcCtD
Sirolimus—Dizziness—Fluorouracil—pancreatic cancer	2.79e-05	0.00031	CcSEcCtD
Sirolimus—Visual impairment—Epirubicin—pancreatic cancer	2.79e-05	0.00031	CcSEcCtD
Sirolimus—Rash—Irinotecan—pancreatic cancer	2.78e-05	0.000309	CcSEcCtD
Sirolimus—Dermatitis—Irinotecan—pancreatic cancer	2.78e-05	0.000308	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	2.78e-05	0.000308	CcSEcCtD
Sirolimus—Headache—Irinotecan—pancreatic cancer	2.76e-05	0.000307	CcSEcCtD
Sirolimus—Insomnia—Docetaxel—pancreatic cancer	2.76e-05	0.000306	CcSEcCtD
Sirolimus—Paraesthesia—Docetaxel—pancreatic cancer	2.74e-05	0.000304	CcSEcCtD
Sirolimus—Vomiting—Gemcitabine—pancreatic cancer	2.73e-05	0.000303	CcSEcCtD
Sirolimus—Dyspnoea—Docetaxel—pancreatic cancer	2.72e-05	0.000302	CcSEcCtD
Sirolimus—Somnolence—Docetaxel—pancreatic cancer	2.71e-05	0.000301	CcSEcCtD
Sirolimus—Rash—Gemcitabine—pancreatic cancer	2.71e-05	0.000301	CcSEcCtD
Sirolimus—Dermatitis—Gemcitabine—pancreatic cancer	2.71e-05	0.0003	CcSEcCtD
Sirolimus—Tinnitus—Epirubicin—pancreatic cancer	2.7e-05	0.0003	CcSEcCtD
Sirolimus—Haemoglobin—Doxorubicin—pancreatic cancer	2.69e-05	0.000299	CcSEcCtD
Sirolimus—Headache—Gemcitabine—pancreatic cancer	2.69e-05	0.000299	CcSEcCtD
Sirolimus—Cardiac disorder—Epirubicin—pancreatic cancer	2.69e-05	0.000298	CcSEcCtD
Sirolimus—Vomiting—Fluorouracil—pancreatic cancer	2.69e-05	0.000298	CcSEcCtD
Sirolimus—Rhinitis—Doxorubicin—pancreatic cancer	2.69e-05	0.000298	CcSEcCtD
Sirolimus—Dyspepsia—Docetaxel—pancreatic cancer	2.68e-05	0.000298	CcSEcCtD
Sirolimus—Haemorrhage—Doxorubicin—pancreatic cancer	2.68e-05	0.000297	CcSEcCtD
Sirolimus—Hypoaesthesia—Doxorubicin—pancreatic cancer	2.66e-05	0.000296	CcSEcCtD
Sirolimus—Rash—Fluorouracil—pancreatic cancer	2.66e-05	0.000296	CcSEcCtD
Sirolimus—Dermatitis—Fluorouracil—pancreatic cancer	2.66e-05	0.000295	CcSEcCtD
Sirolimus—Pharyngitis—Doxorubicin—pancreatic cancer	2.66e-05	0.000295	CcSEcCtD
Sirolimus—Decreased appetite—Docetaxel—pancreatic cancer	2.65e-05	0.000294	CcSEcCtD
Sirolimus—Headache—Fluorouracil—pancreatic cancer	2.65e-05	0.000294	CcSEcCtD
Sirolimus—Urinary tract disorder—Doxorubicin—pancreatic cancer	2.65e-05	0.000294	CcSEcCtD
Sirolimus—Oedema peripheral—Doxorubicin—pancreatic cancer	2.64e-05	0.000293	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Docetaxel—pancreatic cancer	2.63e-05	0.000292	CcSEcCtD
Sirolimus—Connective tissue disorder—Doxorubicin—pancreatic cancer	2.63e-05	0.000292	CcSEcCtD
Sirolimus—Angiopathy—Epirubicin—pancreatic cancer	2.63e-05	0.000291	CcSEcCtD
Sirolimus—Urethral disorder—Doxorubicin—pancreatic cancer	2.63e-05	0.000291	CcSEcCtD
Sirolimus—Nausea—Irinotecan—pancreatic cancer	2.62e-05	0.000291	CcSEcCtD
Sirolimus—Immune system disorder—Epirubicin—pancreatic cancer	2.61e-05	0.00029	CcSEcCtD
Sirolimus—Mediastinal disorder—Epirubicin—pancreatic cancer	2.61e-05	0.00029	CcSEcCtD
Sirolimus—Constipation—Docetaxel—pancreatic cancer	2.61e-05	0.000289	CcSEcCtD
Sirolimus—Pain—Docetaxel—pancreatic cancer	2.61e-05	0.000289	CcSEcCtD
Sirolimus—Chills—Epirubicin—pancreatic cancer	2.6e-05	0.000288	CcSEcCtD
Sirolimus—Visual impairment—Doxorubicin—pancreatic cancer	2.58e-05	0.000286	CcSEcCtD
Sirolimus—Nausea—Gemcitabine—pancreatic cancer	2.55e-05	0.000283	CcSEcCtD
Sirolimus—Malnutrition—Epirubicin—pancreatic cancer	2.52e-05	0.00028	CcSEcCtD
Sirolimus—Feeling abnormal—Docetaxel—pancreatic cancer	2.51e-05	0.000279	CcSEcCtD
Sirolimus—Nausea—Fluorouracil—pancreatic cancer	2.51e-05	0.000278	CcSEcCtD
Sirolimus—Tinnitus—Doxorubicin—pancreatic cancer	2.5e-05	0.000277	CcSEcCtD
Sirolimus—Gastrointestinal pain—Docetaxel—pancreatic cancer	2.49e-05	0.000277	CcSEcCtD
Sirolimus—Cardiac disorder—Doxorubicin—pancreatic cancer	2.49e-05	0.000276	CcSEcCtD
Sirolimus—Flatulence—Epirubicin—pancreatic cancer	2.48e-05	0.000276	CcSEcCtD
Sirolimus—Tension—Epirubicin—pancreatic cancer	2.47e-05	0.000274	CcSEcCtD
Sirolimus—Nervousness—Epirubicin—pancreatic cancer	2.45e-05	0.000272	CcSEcCtD
Sirolimus—Back pain—Epirubicin—pancreatic cancer	2.44e-05	0.00027	CcSEcCtD
Sirolimus—Angiopathy—Doxorubicin—pancreatic cancer	2.43e-05	0.00027	CcSEcCtD
Sirolimus—Muscle spasms—Epirubicin—pancreatic cancer	2.42e-05	0.000269	CcSEcCtD
Sirolimus—Immune system disorder—Doxorubicin—pancreatic cancer	2.42e-05	0.000268	CcSEcCtD
Sirolimus—Mediastinal disorder—Doxorubicin—pancreatic cancer	2.41e-05	0.000268	CcSEcCtD
Sirolimus—Abdominal pain—Docetaxel—pancreatic cancer	2.41e-05	0.000267	CcSEcCtD
Sirolimus—Body temperature increased—Docetaxel—pancreatic cancer	2.41e-05	0.000267	CcSEcCtD
Sirolimus—Chills—Doxorubicin—pancreatic cancer	2.4e-05	0.000267	CcSEcCtD
Sirolimus—Ill-defined disorder—Epirubicin—pancreatic cancer	2.34e-05	0.000259	CcSEcCtD
Sirolimus—Malnutrition—Doxorubicin—pancreatic cancer	2.33e-05	0.000259	CcSEcCtD
Sirolimus—Anaemia—Epirubicin—pancreatic cancer	2.33e-05	0.000258	CcSEcCtD
Sirolimus—Agitation—Epirubicin—pancreatic cancer	2.32e-05	0.000257	CcSEcCtD
Sirolimus—Flatulence—Doxorubicin—pancreatic cancer	2.3e-05	0.000255	CcSEcCtD
Sirolimus—Tension—Doxorubicin—pancreatic cancer	2.29e-05	0.000254	CcSEcCtD
Sirolimus—Malaise—Epirubicin—pancreatic cancer	2.27e-05	0.000252	CcSEcCtD
Sirolimus—Nervousness—Doxorubicin—pancreatic cancer	2.26e-05	0.000251	CcSEcCtD
Sirolimus—Syncope—Epirubicin—pancreatic cancer	2.26e-05	0.000251	CcSEcCtD
Sirolimus—Leukopenia—Epirubicin—pancreatic cancer	2.26e-05	0.00025	CcSEcCtD
Sirolimus—Back pain—Doxorubicin—pancreatic cancer	2.26e-05	0.00025	CcSEcCtD
Sirolimus—Hypersensitivity—Docetaxel—pancreatic cancer	2.25e-05	0.000249	CcSEcCtD
Sirolimus—Muscle spasms—Doxorubicin—pancreatic cancer	2.24e-05	0.000249	CcSEcCtD
Sirolimus—Palpitations—Epirubicin—pancreatic cancer	2.23e-05	0.000247	CcSEcCtD
Sirolimus—Loss of consciousness—Epirubicin—pancreatic cancer	2.21e-05	0.000246	CcSEcCtD
Sirolimus—Cough—Epirubicin—pancreatic cancer	2.2e-05	0.000244	CcSEcCtD
Sirolimus—Asthenia—Docetaxel—pancreatic cancer	2.19e-05	0.000243	CcSEcCtD
Sirolimus—Hypertension—Epirubicin—pancreatic cancer	2.18e-05	0.000241	CcSEcCtD
Sirolimus—Ill-defined disorder—Doxorubicin—pancreatic cancer	2.16e-05	0.00024	CcSEcCtD
Sirolimus—Pruritus—Docetaxel—pancreatic cancer	2.16e-05	0.000239	CcSEcCtD
Sirolimus—Anaemia—Doxorubicin—pancreatic cancer	2.15e-05	0.000239	CcSEcCtD
Sirolimus—Arthralgia—Epirubicin—pancreatic cancer	2.15e-05	0.000238	CcSEcCtD
Sirolimus—Myalgia—Epirubicin—pancreatic cancer	2.15e-05	0.000238	CcSEcCtD
Sirolimus—Chest pain—Epirubicin—pancreatic cancer	2.15e-05	0.000238	CcSEcCtD
Sirolimus—Agitation—Doxorubicin—pancreatic cancer	2.14e-05	0.000238	CcSEcCtD
Sirolimus—Anxiety—Epirubicin—pancreatic cancer	2.14e-05	0.000237	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	2.13e-05	0.000236	CcSEcCtD
Sirolimus—Discomfort—Epirubicin—pancreatic cancer	2.12e-05	0.000235	CcSEcCtD
Sirolimus—Malaise—Doxorubicin—pancreatic cancer	2.1e-05	0.000233	CcSEcCtD
Sirolimus—Syncope—Doxorubicin—pancreatic cancer	2.09e-05	0.000232	CcSEcCtD
Sirolimus—Leukopenia—Doxorubicin—pancreatic cancer	2.09e-05	0.000232	CcSEcCtD
Sirolimus—Diarrhoea—Docetaxel—pancreatic cancer	2.09e-05	0.000232	CcSEcCtD
Sirolimus—Confusional state—Epirubicin—pancreatic cancer	2.07e-05	0.00023	CcSEcCtD
Sirolimus—Palpitations—Doxorubicin—pancreatic cancer	2.06e-05	0.000229	CcSEcCtD
Sirolimus—Anaphylactic shock—Epirubicin—pancreatic cancer	2.06e-05	0.000228	CcSEcCtD
Sirolimus—Oedema—Epirubicin—pancreatic cancer	2.06e-05	0.000228	CcSEcCtD
Sirolimus—Loss of consciousness—Doxorubicin—pancreatic cancer	2.05e-05	0.000227	CcSEcCtD
Sirolimus—Infection—Epirubicin—pancreatic cancer	2.04e-05	0.000227	CcSEcCtD
Sirolimus—Cough—Doxorubicin—pancreatic cancer	2.03e-05	0.000226	CcSEcCtD
Sirolimus—Shock—Epirubicin—pancreatic cancer	2.02e-05	0.000225	CcSEcCtD
Sirolimus—Nervous system disorder—Epirubicin—pancreatic cancer	2.02e-05	0.000224	CcSEcCtD
Sirolimus—Dizziness—Docetaxel—pancreatic cancer	2.02e-05	0.000224	CcSEcCtD
Sirolimus—Thrombocytopenia—Epirubicin—pancreatic cancer	2.01e-05	0.000223	CcSEcCtD
Sirolimus—Hypertension—Doxorubicin—pancreatic cancer	2.01e-05	0.000223	CcSEcCtD
Sirolimus—Tachycardia—Epirubicin—pancreatic cancer	2.01e-05	0.000223	CcSEcCtD
Sirolimus—Skin disorder—Epirubicin—pancreatic cancer	2e-05	0.000222	CcSEcCtD
Sirolimus—Hyperhidrosis—Epirubicin—pancreatic cancer	1.99e-05	0.000221	CcSEcCtD
Sirolimus—Chest pain—Doxorubicin—pancreatic cancer	1.99e-05	0.00022	CcSEcCtD
Sirolimus—Myalgia—Doxorubicin—pancreatic cancer	1.99e-05	0.00022	CcSEcCtD
Sirolimus—Arthralgia—Doxorubicin—pancreatic cancer	1.99e-05	0.00022	CcSEcCtD
Sirolimus—Anxiety—Doxorubicin—pancreatic cancer	1.98e-05	0.00022	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	1.97e-05	0.000219	CcSEcCtD
Sirolimus—Discomfort—Doxorubicin—pancreatic cancer	1.96e-05	0.000218	CcSEcCtD
Sirolimus—Anorexia—Epirubicin—pancreatic cancer	1.96e-05	0.000218	CcSEcCtD
Sirolimus—Vomiting—Docetaxel—pancreatic cancer	1.94e-05	0.000215	CcSEcCtD
Sirolimus—Rash—Docetaxel—pancreatic cancer	1.92e-05	0.000213	CcSEcCtD
Sirolimus—Hypotension—Epirubicin—pancreatic cancer	1.92e-05	0.000213	CcSEcCtD
Sirolimus—Dermatitis—Docetaxel—pancreatic cancer	1.92e-05	0.000213	CcSEcCtD
Sirolimus—Confusional state—Doxorubicin—pancreatic cancer	1.92e-05	0.000213	CcSEcCtD
Sirolimus—Headache—Docetaxel—pancreatic cancer	1.91e-05	0.000212	CcSEcCtD
Sirolimus—Oedema—Doxorubicin—pancreatic cancer	1.9e-05	0.000211	CcSEcCtD
Sirolimus—Anaphylactic shock—Doxorubicin—pancreatic cancer	1.9e-05	0.000211	CcSEcCtD
Sirolimus—Infection—Doxorubicin—pancreatic cancer	1.89e-05	0.00021	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	1.87e-05	0.000208	CcSEcCtD
Sirolimus—Shock—Doxorubicin—pancreatic cancer	1.87e-05	0.000208	CcSEcCtD
Sirolimus—Nervous system disorder—Doxorubicin—pancreatic cancer	1.87e-05	0.000207	CcSEcCtD
Sirolimus—Thrombocytopenia—Doxorubicin—pancreatic cancer	1.86e-05	0.000207	CcSEcCtD
Sirolimus—Insomnia—Epirubicin—pancreatic cancer	1.86e-05	0.000206	CcSEcCtD
Sirolimus—Tachycardia—Doxorubicin—pancreatic cancer	1.86e-05	0.000206	CcSEcCtD
Sirolimus—Skin disorder—Doxorubicin—pancreatic cancer	1.85e-05	0.000205	CcSEcCtD
Sirolimus—Paraesthesia—Epirubicin—pancreatic cancer	1.85e-05	0.000205	CcSEcCtD
Sirolimus—Hyperhidrosis—Doxorubicin—pancreatic cancer	1.84e-05	0.000204	CcSEcCtD
Sirolimus—Dyspnoea—Epirubicin—pancreatic cancer	1.83e-05	0.000203	CcSEcCtD
Sirolimus—Somnolence—Epirubicin—pancreatic cancer	1.83e-05	0.000203	CcSEcCtD
Sirolimus—Anorexia—Doxorubicin—pancreatic cancer	1.81e-05	0.000201	CcSEcCtD
Sirolimus—Nausea—Docetaxel—pancreatic cancer	1.81e-05	0.000201	CcSEcCtD
Sirolimus—Dyspepsia—Epirubicin—pancreatic cancer	1.81e-05	0.000201	CcSEcCtD
Sirolimus—Decreased appetite—Epirubicin—pancreatic cancer	1.79e-05	0.000198	CcSEcCtD
Sirolimus—Hypotension—Doxorubicin—pancreatic cancer	1.78e-05	0.000197	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Epirubicin—pancreatic cancer	1.78e-05	0.000197	CcSEcCtD
Sirolimus—Pain—Epirubicin—pancreatic cancer	1.76e-05	0.000195	CcSEcCtD
Sirolimus—Constipation—Epirubicin—pancreatic cancer	1.76e-05	0.000195	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	1.73e-05	0.000192	CcSEcCtD
Sirolimus—Insomnia—Doxorubicin—pancreatic cancer	1.72e-05	0.000191	CcSEcCtD
Sirolimus—Paraesthesia—Doxorubicin—pancreatic cancer	1.71e-05	0.00019	CcSEcCtD
Sirolimus—Dyspnoea—Doxorubicin—pancreatic cancer	1.7e-05	0.000188	CcSEcCtD
Sirolimus—Feeling abnormal—Epirubicin—pancreatic cancer	1.69e-05	0.000188	CcSEcCtD
Sirolimus—Somnolence—Doxorubicin—pancreatic cancer	1.69e-05	0.000188	CcSEcCtD
Sirolimus—Gastrointestinal pain—Epirubicin—pancreatic cancer	1.68e-05	0.000187	CcSEcCtD
Sirolimus—Dyspepsia—Doxorubicin—pancreatic cancer	1.68e-05	0.000186	CcSEcCtD
Sirolimus—Decreased appetite—Doxorubicin—pancreatic cancer	1.65e-05	0.000184	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	1.64e-05	0.000182	CcSEcCtD
Sirolimus—Pain—Doxorubicin—pancreatic cancer	1.63e-05	0.000181	CcSEcCtD
Sirolimus—Constipation—Doxorubicin—pancreatic cancer	1.63e-05	0.000181	CcSEcCtD
Sirolimus—Abdominal pain—Epirubicin—pancreatic cancer	1.63e-05	0.00018	CcSEcCtD
Sirolimus—Body temperature increased—Epirubicin—pancreatic cancer	1.63e-05	0.00018	CcSEcCtD
Sirolimus—Feeling abnormal—Doxorubicin—pancreatic cancer	1.57e-05	0.000174	CcSEcCtD
Sirolimus—Gastrointestinal pain—Doxorubicin—pancreatic cancer	1.56e-05	0.000173	CcSEcCtD
Sirolimus—Hypersensitivity—Epirubicin—pancreatic cancer	1.52e-05	0.000168	CcSEcCtD
Sirolimus—Abdominal pain—Doxorubicin—pancreatic cancer	1.5e-05	0.000167	CcSEcCtD
Sirolimus—Body temperature increased—Doxorubicin—pancreatic cancer	1.5e-05	0.000167	CcSEcCtD
Sirolimus—Asthenia—Epirubicin—pancreatic cancer	1.48e-05	0.000164	CcSEcCtD
Sirolimus—Pruritus—Epirubicin—pancreatic cancer	1.46e-05	0.000161	CcSEcCtD
Sirolimus—Diarrhoea—Epirubicin—pancreatic cancer	1.41e-05	0.000156	CcSEcCtD
Sirolimus—Hypersensitivity—Doxorubicin—pancreatic cancer	1.4e-05	0.000156	CcSEcCtD
Sirolimus—Asthenia—Doxorubicin—pancreatic cancer	1.37e-05	0.000152	CcSEcCtD
Sirolimus—Dizziness—Epirubicin—pancreatic cancer	1.36e-05	0.000151	CcSEcCtD
Sirolimus—Pruritus—Doxorubicin—pancreatic cancer	1.35e-05	0.000149	CcSEcCtD
Sirolimus—Vomiting—Epirubicin—pancreatic cancer	1.31e-05	0.000145	CcSEcCtD
Sirolimus—Diarrhoea—Doxorubicin—pancreatic cancer	1.3e-05	0.000144	CcSEcCtD
Sirolimus—Rash—Epirubicin—pancreatic cancer	1.3e-05	0.000144	CcSEcCtD
Sirolimus—Dermatitis—Epirubicin—pancreatic cancer	1.3e-05	0.000144	CcSEcCtD
Sirolimus—Headache—Epirubicin—pancreatic cancer	1.29e-05	0.000143	CcSEcCtD
Sirolimus—Dizziness—Doxorubicin—pancreatic cancer	1.26e-05	0.00014	CcSEcCtD
Sirolimus—Nausea—Epirubicin—pancreatic cancer	1.22e-05	0.000136	CcSEcCtD
Sirolimus—Vomiting—Doxorubicin—pancreatic cancer	1.21e-05	0.000134	CcSEcCtD
Sirolimus—Rash—Doxorubicin—pancreatic cancer	1.2e-05	0.000133	CcSEcCtD
Sirolimus—Dermatitis—Doxorubicin—pancreatic cancer	1.2e-05	0.000133	CcSEcCtD
Sirolimus—Headache—Doxorubicin—pancreatic cancer	1.19e-05	0.000132	CcSEcCtD
Sirolimus—Nausea—Doxorubicin—pancreatic cancer	1.13e-05	0.000125	CcSEcCtD
Sirolimus—FGF2—Developmental Biology—AKT1—pancreatic cancer	5.2e-06	8.41e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HIF1A—pancreatic cancer	5.15e-06	8.32e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	5.15e-06	8.32e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EGF—pancreatic cancer	5.15e-06	8.32e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TSC2—pancreatic cancer	5.14e-06	8.3e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	5.13e-06	8.29e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	5.11e-06	8.27e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—NRAS—pancreatic cancer	5.07e-06	8.19e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—STAT3—pancreatic cancer	5.06e-06	8.18e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—NRAS—pancreatic cancer	5.05e-06	8.16e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—STK11—pancreatic cancer	5.03e-06	8.13e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—APOE—pancreatic cancer	5.03e-06	8.12e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	5.02e-06	8.11e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—SRC—pancreatic cancer	5.01e-06	8.1e-05	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—HRAS—pancreatic cancer	5e-06	8.08e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—PIK3CB—pancreatic cancer	4.96e-06	8.02e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KDR—pancreatic cancer	4.92e-06	7.96e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—PTGS2—pancreatic cancer	4.92e-06	7.95e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—NOTCH1—pancreatic cancer	4.91e-06	7.94e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—VEGFA—pancreatic cancer	4.88e-06	7.89e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—STAT3—pancreatic cancer	4.83e-06	7.81e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—NRAS—pancreatic cancer	4.82e-06	7.79e-05	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—AKT1—pancreatic cancer	4.82e-06	7.78e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—EGFR—pancreatic cancer	4.81e-06	7.77e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDH1—pancreatic cancer	4.79e-06	7.74e-05	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—AKT1—pancreatic cancer	4.79e-06	7.74e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	4.78e-06	7.72e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CTNNB1—pancreatic cancer	4.77e-06	7.7e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—EGF—pancreatic cancer	4.75e-06	7.68e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	4.74e-06	7.66e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—TYMS—pancreatic cancer	4.72e-06	7.62e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MYC—pancreatic cancer	4.7e-06	7.6e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—TGFB1—pancreatic cancer	4.69e-06	7.58e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NFKBIA—pancreatic cancer	4.68e-06	7.57e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SMAD4—pancreatic cancer	4.67e-06	7.55e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PTEN—pancreatic cancer	4.64e-06	7.51e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NOTCH1—pancreatic cancer	4.64e-06	7.5e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—EGFR—pancreatic cancer	4.62e-06	7.47e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—EGFR—pancreatic cancer	4.6e-06	7.43e-05	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—AKT1—pancreatic cancer	4.6e-06	7.43e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PIK3CB—pancreatic cancer	4.59e-06	7.41e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PIK3CD—pancreatic cancer	4.58e-06	7.4e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HES1—pancreatic cancer	4.56e-06	7.37e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—KRAS—pancreatic cancer	4.54e-06	7.34e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CG—pancreatic cancer	4.54e-06	7.33e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MYC—pancreatic cancer	4.49e-06	7.26e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EGF—pancreatic cancer	4.48e-06	7.25e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TGFB1—pancreatic cancer	4.48e-06	7.24e-05	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—AKT1—pancreatic cancer	4.41e-06	7.13e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CXCL8—pancreatic cancer	4.41e-06	7.12e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—CTNNB1—pancreatic cancer	4.4e-06	7.11e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EGFR—pancreatic cancer	4.39e-06	7.1e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—KRAS—pancreatic cancer	4.36e-06	7.05e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	4.35e-06	7.03e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—KRAS—pancreatic cancer	4.35e-06	7.02e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—TYMS—pancreatic cancer	4.33e-06	7e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—SRC—pancreatic cancer	4.31e-06	6.96e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—PTEN—pancreatic cancer	4.29e-06	6.93e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PRSS1—pancreatic cancer	4.25e-06	6.87e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PIK3CD—pancreatic cancer	4.23e-06	6.83e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CASP3—pancreatic cancer	4.22e-06	6.82e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GLP1R—pancreatic cancer	4.21e-06	6.81e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	4.21e-06	6.81e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—PIK3CA—pancreatic cancer	4.18e-06	6.75e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—STAT3—pancreatic cancer	4.15e-06	6.71e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—KRAS—pancreatic cancer	4.15e-06	6.7e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—NRAS—pancreatic cancer	4.14e-06	6.7e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—DPYD—pancreatic cancer	4.14e-06	6.7e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCND1—pancreatic cancer	4.11e-06	6.64e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CTNNB1—pancreatic cancer	4.07e-06	6.57e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CD44—pancreatic cancer	4.04e-06	6.52e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—PIK3CA—pancreatic cancer	4.01e-06	6.48e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TERT—pancreatic cancer	3.99e-06	6.46e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PIK3CA—pancreatic cancer	3.99e-06	6.45e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PIK3CB—pancreatic cancer	3.99e-06	6.45e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CD—pancreatic cancer	3.99e-06	6.44e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MMP9—pancreatic cancer	3.99e-06	6.44e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—SRC—pancreatic cancer	3.98e-06	6.43e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PTEN—pancreatic cancer	3.96e-06	6.4e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SLC2A2—pancreatic cancer	3.93e-06	6.35e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GCG—pancreatic cancer	3.87e-06	6.25e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—HRAS—pancreatic cancer	3.86e-06	6.24e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—APOE—pancreatic cancer	3.84e-06	6.2e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—STAT3—pancreatic cancer	3.84e-06	6.2e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—NRAS—pancreatic cancer	3.83e-06	6.18e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HIF1A—pancreatic cancer	3.82e-06	6.17e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PIK3CA—pancreatic cancer	3.81e-06	6.16e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TSC2—pancreatic cancer	3.81e-06	6.16e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EGFR—pancreatic cancer	3.78e-06	6.1e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—APOE—pancreatic cancer	3.73e-06	6.03e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HRAS—pancreatic cancer	3.71e-06	5.99e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HRAS—pancreatic cancer	3.69e-06	5.97e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—pancreatic cancer	3.69e-06	5.96e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PIK3CB—pancreatic cancer	3.68e-06	5.95e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ARG2—pancreatic cancer	3.68e-06	5.95e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SRC—pancreatic cancer	3.67e-06	5.94e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KDR—pancreatic cancer	3.65e-06	5.91e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTGS2—pancreatic cancer	3.65e-06	5.9e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—STK11—pancreatic cancer	3.64e-06	5.88e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	3.63e-06	5.87e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—VEGFA—pancreatic cancer	3.58e-06	5.78e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KRAS—pancreatic cancer	3.57e-06	5.76e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MYC—pancreatic cancer	3.56e-06	5.76e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	3.56e-06	5.75e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—TGFB1—pancreatic cancer	3.56e-06	5.75e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—STAT3—pancreatic cancer	3.54e-06	5.73e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CTNNB1—pancreatic cancer	3.54e-06	5.72e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NRAS—pancreatic cancer	3.54e-06	5.71e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HRAS—pancreatic cancer	3.53e-06	5.7e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—APOE—pancreatic cancer	3.52e-06	5.69e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—EGFR—pancreatic cancer	3.49e-06	5.63e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CB—pancreatic cancer	3.48e-06	5.62e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NFKBIA—pancreatic cancer	3.48e-06	5.62e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CG—pancreatic cancer	3.46e-06	5.59e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PTEN—pancreatic cancer	3.45e-06	5.57e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NOTCH1—pancreatic cancer	3.44e-06	5.56e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—AKT1—pancreatic cancer	3.41e-06	5.51e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CG—pancreatic cancer	3.37e-06	5.44e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PPARG—pancreatic cancer	3.34e-06	5.4e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CXCL8—pancreatic cancer	3.34e-06	5.4e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EGF—pancreatic cancer	3.33e-06	5.38e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MYC—pancreatic cancer	3.29e-06	5.32e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—KRAS—pancreatic cancer	3.29e-06	5.32e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TGFB1—pancreatic cancer	3.29e-06	5.31e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PIK3CA—pancreatic cancer	3.28e-06	5.3e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—AKT1—pancreatic cancer	3.28e-06	5.29e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CTNNB1—pancreatic cancer	3.27e-06	5.28e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—AKT1—pancreatic cancer	3.26e-06	5.27e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EGFR—pancreatic cancer	3.22e-06	5.21e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TYMP—pancreatic cancer	3.22e-06	5.2e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—SRC—pancreatic cancer	3.2e-06	5.17e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CASP3—pancreatic cancer	3.2e-06	5.17e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTEN—pancreatic cancer	3.18e-06	5.14e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CG—pancreatic cancer	3.18e-06	5.13e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—TYMS—pancreatic cancer	3.13e-06	5.06e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—AKT1—pancreatic cancer	3.11e-06	5.03e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCND1—pancreatic cancer	3.11e-06	5.03e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—STAT3—pancreatic cancer	3.08e-06	4.98e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CTNNB1—pancreatic cancer	3.08e-06	4.98e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—NRAS—pancreatic cancer	3.08e-06	4.97e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PPARG—pancreatic cancer	3.07e-06	4.96e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CD44—pancreatic cancer	3.04e-06	4.92e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CD—pancreatic cancer	3.04e-06	4.92e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KRAS—pancreatic cancer	3.04e-06	4.92e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HRAS—pancreatic cancer	3.03e-06	4.9e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—PIK3CA—pancreatic cancer	3.03e-06	4.89e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MMP9—pancreatic cancer	3.02e-06	4.88e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PTEN—pancreatic cancer	3e-06	4.85e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CD—pancreatic cancer	2.96e-06	4.78e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—SRC—pancreatic cancer	2.95e-06	4.77e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GCG—pancreatic cancer	2.92e-06	4.72e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—STAT3—pancreatic cancer	2.85e-06	4.6e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—NRAS—pancreatic cancer	2.84e-06	4.59e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EGFR—pancreatic cancer	2.8e-06	4.53e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—HRAS—pancreatic cancer	2.8e-06	4.52e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PIK3CA—pancreatic cancer	2.8e-06	4.52e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CD—pancreatic cancer	2.79e-06	4.51e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SRC—pancreatic cancer	2.78e-06	4.5e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—STK11—pancreatic cancer	2.74e-06	4.44e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—VEGFA—pancreatic cancer	2.71e-06	4.38e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—pancreatic cancer	2.7e-06	4.37e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—STAT3—pancreatic cancer	2.69e-06	4.34e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NRAS—pancreatic cancer	2.68e-06	4.33e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—AKT1—pancreatic cancer	2.68e-06	4.33e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CB—pancreatic cancer	2.65e-06	4.29e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KRAS—pancreatic cancer	2.65e-06	4.28e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MYC—pancreatic cancer	2.64e-06	4.27e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—TGFB1—pancreatic cancer	2.64e-06	4.26e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTGS2—pancreatic cancer	2.63e-06	4.25e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GLP1R—pancreatic cancer	2.59e-06	4.19e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—EGFR—pancreatic cancer	2.59e-06	4.18e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HRAS—pancreatic cancer	2.59e-06	4.18e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CB—pancreatic cancer	2.58e-06	4.17e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—DPYD—pancreatic cancer	2.55e-06	4.13e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—APOE—pancreatic cancer	2.54e-06	4.11e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MYC—pancreatic cancer	2.5e-06	4.03e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TGFB1—pancreatic cancer	2.49e-06	4.02e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CXCL8—pancreatic cancer	2.48e-06	4.01e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—AKT1—pancreatic cancer	2.47e-06	3.99e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—KRAS—pancreatic cancer	2.44e-06	3.95e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EGFR—pancreatic cancer	2.44e-06	3.95e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CB—pancreatic cancer	2.43e-06	3.93e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PIK3CA—pancreatic cancer	2.43e-06	3.93e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	2.42e-06	3.92e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTGS2—pancreatic cancer	2.41e-06	3.9e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CASP3—pancreatic cancer	2.37e-06	3.83e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TYMS—pancreatic cancer	2.36e-06	3.82e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCND1—pancreatic cancer	2.31e-06	3.73e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KRAS—pancreatic cancer	2.31e-06	3.73e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CG—pancreatic cancer	2.3e-06	3.71e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTEN—pancreatic cancer	2.29e-06	3.7e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CTNNB1—pancreatic cancer	2.29e-06	3.7e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AKT1—pancreatic cancer	2.28e-06	3.69e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HRAS—pancreatic cancer	2.25e-06	3.64e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PIK3CA—pancreatic cancer	2.25e-06	3.63e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MMP9—pancreatic cancer	2.24e-06	3.62e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PTEN—pancreatic cancer	2.23e-06	3.6e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PPARG—pancreatic cancer	2.22e-06	3.58e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CA—pancreatic cancer	2.12e-06	3.42e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTEN—pancreatic cancer	2.1e-06	3.4e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—HRAS—pancreatic cancer	2.08e-06	3.36e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SRC—pancreatic cancer	2.07e-06	3.34e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—pancreatic cancer	2.05e-06	3.31e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CD—pancreatic cancer	2.02e-06	3.26e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—VEGFA—pancreatic cancer	2.01e-06	3.25e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—STAT3—pancreatic cancer	1.99e-06	3.22e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NRAS—pancreatic cancer	1.99e-06	3.21e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—AKT1—pancreatic cancer	1.99e-06	3.21e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HRAS—pancreatic cancer	1.96e-06	3.17e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—APOE—pancreatic cancer	1.92e-06	3.1e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CD44—pancreatic cancer	1.88e-06	3.03e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MYC—pancreatic cancer	1.85e-06	2.99e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TGFB1—pancreatic cancer	1.85e-06	2.99e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—AKT1—pancreatic cancer	1.83e-06	2.96e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EGFR—pancreatic cancer	1.81e-06	2.93e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GCG—pancreatic cancer	1.8e-06	2.91e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	1.76e-06	2.84e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTGS2—pancreatic cancer	1.74e-06	2.82e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CG—pancreatic cancer	1.73e-06	2.8e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AKT1—pancreatic cancer	1.73e-06	2.8e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KRAS—pancreatic cancer	1.71e-06	2.77e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—STK11—pancreatic cancer	1.69e-06	2.73e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PPARG—pancreatic cancer	1.67e-06	2.7e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CA—pancreatic cancer	1.62e-06	2.61e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CA—pancreatic cancer	1.57e-06	2.54e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CD—pancreatic cancer	1.52e-06	2.46e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—pancreatic cancer	1.52e-06	2.46e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTEN—pancreatic cancer	1.52e-06	2.46e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CA—pancreatic cancer	1.48e-06	2.4e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TYMS—pancreatic cancer	1.45e-06	2.35e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HRAS—pancreatic cancer	1.45e-06	2.35e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CB—pancreatic cancer	1.33e-06	2.15e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—AKT1—pancreatic cancer	1.32e-06	2.13e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTGS2—pancreatic cancer	1.32e-06	2.13e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AKT1—pancreatic cancer	1.28e-06	2.08e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—AKT1—pancreatic cancer	1.21e-06	1.96e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—APOE—pancreatic cancer	1.18e-06	1.91e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTEN—pancreatic cancer	1.15e-06	1.85e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	1.07e-06	1.73e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	1.07e-06	1.73e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PPARG—pancreatic cancer	1.03e-06	1.67e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	9.39e-07	1.52e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—AKT1—pancreatic cancer	8.76e-07	1.42e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	8.18e-07	1.32e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTGS2—pancreatic cancer	8.11e-07	1.31e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CA—pancreatic cancer	8.09e-07	1.31e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTEN—pancreatic cancer	7.07e-07	1.14e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AKT1—pancreatic cancer	6.61e-07	1.07e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	4.99e-07	8.06e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AKT1—pancreatic cancer	4.07e-07	6.58e-06	CbGpPWpGaD
